• Explore /
  • Poster
  • / Relationship between fluoropyrimidine (FPD) exposure and outcomes in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.

Relationship between fluoropyrimidine (FPD) exposure and outcomes in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.

Abstract Poster

Authors

null

Marwan Fakih

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA

Marwan Fakih , Gerald W. Prager , Julien Taieb , Elizabeth Martine Calleja , Mei Liu , Nadia Amellal , Josep Tabernero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04737187

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 114)

DOI

10.1200/JCO.2024.42.3_suppl.114

Abstract #

114

Poster Bd #

G18

Abstract Disclosures

Similar Posters

First Author: Timothy Jay Price

First Author: Annika Kurreck

First Author: Mohamed E. Salem

First Author: Julien Taieb